SCHEMBL2293586

SCHEMBL2293586

Cc1cccc(C)c1Nc1c(-c2ccccc2OCC(N)=O)nc2cccc(F)n12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.53
TP53 P04637 6/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
KCNN4 O15554 1/20 0.39
ADORA1 P30542 1/20 0.37
GAA P10253 9/20 0.37
KMT2A Q03164 2/20 0.37
HTT P42858 2/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288371 0.94 MAPT (0.46) MAPTTP53SMN1; SMN2KCNN4ADORA1
SCHEMBL2293506 0.92 MAPT (0.46) MAPTTP53SMN1; SMN2KCNN4GAA
SCHEMBL2292943 0.90 SMN1; SMN2 (0.61) MAPTTP53SMN1; SMN2ADORA1GAA
SCHEMBL2290049 0.89 MAPT (0.48) MAPTTP53SMN1; SMN2KCNN4ADORA1
SCHEMBL2293410 0.89 MAPT (0.48) MAPTTP53SMN1; SMN2KCNN4ADORA1
SCHEMBL2289665 0.87 MAPT (0.42) MAPTTP53SMN1; SMN2GAAKMT2A
SCHEMBL2288504 0.85 GAA (0.54) MAPTTP53SMN1; SMN2GAAKMT2A
SCHEMBL2294046 0.84 SMN1; SMN2 (0.53) MAPTTP53SMN1; SMN2ADORA1GAA
SCHEMBL2287174 0.84 GAA (0.44) MAPTTP53SMN1; SMN2KCNN4ADORA1
SCHEMBL2816809 0.83 GAA (0.53) MAPTTP53SMN1; SMN2KCNN4ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 MAPT 1138/4885TP53 4410/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.